P have been used for mitral and aortic valve replacement
|
|
- Natalie Riley
- 6 years ago
- Views:
Transcription
1 A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani, MD, Y. Stephan, MD, P. Blondeau, MD, and A. Carpentier, MD, PhD Department of Cardiovascular Surgery, HBpital Broussais, Paris, France Two hundred fifty-three patients who underwent isolated mitral valve replacement with a porcine bioprosthesis had long-term evaluation. One hundred fortyseven patients received a Carpentier-Edwards porcine bioprosthesis and 6, a Hancock valve. There were no significant differences in preoperative clinical characteristics between the two groups. Cumulative follow-up was,375 patient-years. At years, 93% 2 2.5% of the patients in the Carpentier-Edwards group and 85% f 7.8% of those in the Hancock group were free from valve-related death (not significant), and 95% f 2% and 9% f 3.8%, respectively, were free from thromboembolism (not significant). At years, 65% f 7.2% of the patients in the Carpentier-Edwards group and 66% f 7.2% of those in the Hancock group were free from structural valve deterioration (not significant), and 64% f 6% and 59% f 7.3%, respectively, were free from reoperation (not significant). We conclude that the first generation of Carpentier-Edwards and Hancock prostheses produce comparable long-term results in the mitral position. (Ann Thorac Surg 989;48:54-9) orcine bioprostheses treated with glutaraldehyde P have been used for mitral and aortic valve replacement since 968 [l]. However, only since 974 has the bioprosthetic valve been commercially available and widely implanted. The Carpentier-Edwards prosthesis and the Hancock prosthesis have been the most frequently used porcine bioprostheses. They differ somewhat in the glutaraldehyde concentration and the type of supporting stent. During the period January 975 to December 979, both types of porcine bioprostheses were commonly used in our institution without special selection or randomization; the choice depended mainly on the preference of the individual surgeon. The aim of this study was to compare long-term performance characteristics of Hancock or Carpentier-Edwards porcine mitral bioprostheses implanted in the same institution by the same team and over the same period. Material and Methods Two hundred fifty-three patients who underwent isolated mitral valve replacement with a porcine bioprosthesis between January 975 and December 979 constitute the material of this study. They were separated into two groups based on the type of valve implanted: 47 patients received a Carpentier-Edwards valve and 6, a Hancock Accepted for publication Jan 2, 989. Address reprint requests to Dr Perier, Clinique de Chirurgie Cardio- Vasculaire HBpital Broussais, 96, rue Didot, 754 Paris, France. valve. Age ranged from 8 to 77 years (mean age, 53.6 &.3 years and 5.2 * 3.3 years, respectively). Analysis of multiple preoperative variables-mean age, proportion of patients aged less than and more than 35 and 55 years, mean preoperative functional class, mean cardiothoracic ratio, incidence of atrial fibrillation, mitral valve lesion, and etiology-did not show any significant differences between the two cohorts (Table ). nformation on operative mortality and complications was collected as part of the follow-up. Long-term followup was completed over a 4-month interval (January through April 987) through questionnaires and telephone contacts with patients and their referring physicians. The average duration of follow-up of surviving patients was years for the Carpentier-Edwards group and years for the Hancock group (range, 7 to 2 years). The cumulative follow-up was 826 patientyears for the Carpentier-Edwards group and 549 patientyears for the Hancock group. Postoperative Anticoagulation All patients received immediate postoperative anticoagulant therapy with subcutaneous administration of heparin sodium beginning six hours after operation and continuing for ten days thereafter. Oral anticoagulation with warfarin sodium was initiated at that time and was eventually discontinued after 3 months depending on the decision of the referring cardiologist, rather than that of the surgeon, provided the patient was in sinus rhythm. Seventy-five percent Of the surviving patients in both groups are on a regimen of long-term anticoagulation. 989 by The Society of Thoracic Surgeons /89/$3.5
2 Ann Thorac Surg 989:48:54-9 PERER ET AL 55 Table. Preoperative Clinical Characteristics of the Two Patient Groupsa4 Variable Age Mean (yr) Patients <35 yr Patients >35 yr Patients <55 yr Patients >55 yr Preoperative functional class Preoperative cardiothoracic ratio Cardiac rhythm Sinus rhythm Atrial fibrillation Predominant functional lesion Mitral stenosis Mitral regurgitation Mixed mitral lesions Etiology Rheumatic fever Degenerative disease schemic disease Endocarditis Previous prosthesis Carpentier- Edwards Hancock (n = 47) (n = 6) 53.6? t.7.6?.7 52 (35) 95 (65) 27 (8) 48 (33) 72 (49) 3 (7) 37 (25) 3 (2) 2 () 2 () 5.2 rf: ?.6.59?.6 3 (2) 93 (88) 7 (6) 3 (28) 59 (56) a There were no significant differences between the two groups. Where applicable, data are shown as the mean? the standard deviation. Numbers in parentheses are percentages. Definitions Stringent definitions for all valve-related complications derived from the Stanford framework were used in this study [2]. Structural valve deterioration was defined as an intrinsic abnormality of the prosthesis (leaflet disruption, calcification) causing stenosis or regurgitation found at autopsy or reoperation. - 5t6 d b C-E HCK ' Fig. Actuarial survival curves. Operative mortality is included. (C-E = Carpentier-Edwards; HCK = Hancock.) Thromboembolism was defined as the occurrence of any new focal neurological deficit, whether transient or permanent, unless it could be proved unequivocally to be due to another cause. Peripheral emboli were also included in this category unless the embolus clearly did not arise from the heart. This category also included valve thrombosis. Anticoagulant-related hemorrhage included all episodes of internal or external bleeding resulting in hospitalization, transfusion, or death. Reoperation included all valve reoperations regardless of the indication, including re-replacement and suturing of a periprosthetic leak. Valve failure encompassed all valve-related complications prompting reoperation or causing death (structural valve deterioration, prosthetic valve endocarditis, periprosthetic leak, hemodynamic valvular dysfunction, thromboembolism, anticoagulant-related hemorrhage). Valve-related death was defined as valve failure leading to death. Statistical Analysis Standard actuarial and linearized techniques were used to describe survival and the incidence of valve-related complications [3-5. The log-rank test was used to compare actuarial curves [6]. Continuous data are presented as the mean? the standard error of the mean. Patients continued in the study until valve removal, death, or loss to follow-up. Patients were removed "alive" Table 2. Causes of Hospital Death" Cause Valve thrombosis Cardiac failure Myocardial infarction Aortic dissection Surgical hemorrhagic complication Sudden death Sepsis Total a Numbers in parentheses are percentages Carpentier-Edwards (n = 47) (8.8) Hancock (n = 6) (7.9) Table 3. Causes of Late Death Cause Carpentier-Edwards (n = 47) Valve-related death 7 Cardiac-related 2 death Sudden death 9 Noncardiac Cancer 4 Other 3 Unknown 4 Total 39 Hancock (n = 6)
3 56 PERER ET AL Ann Thorac Surg 989;48: : i L 93f2 5 9 *-.a 85f C-E HCK Table 5. Causes of Valve-Related Death Carpentier-Edwards Hancock Cause (n = 47) (n = 6) Valvular thrombotic 2 occlusion Thromboembolism Anticoagulant-related 4 hemorrhage Structural valve deterioration 3 Total 7 4 from the study when the original valve was replaced or when an additional valve replacement was required. Only the first event for each patient during the study was considered for the actuarial analysis, whereas all events for each patient were considered in the linear analysis. Results Operative Mortality Thirty-day operative mortality was 8.8% in the Carpentier-Edwards group and 7.9% in the Hancock group. The causes of death are listed in Table 2. One of the early deaths in each group was valve related (valve thrombosis). Late Survival Long-term actuarial survival is shown in Figure. Tenyear survival rates were 55% & 4.7% in the Carpentier- Edwards group and 5% & 6% in the Hancock group. The difference between the two groups was not significant. The causes of late death were grouped into five different categories: valve-related death, cardiac-related death, sudden death, noncardiac cause, and unknown (Table 3). Table 4. Summary of Linearized Rates of Valve-Related Valve- Related Deaths At years, 93% 2 2.5% of the patients in the Carpentier- Edwards group and 85% & 7.8% of those in the Hancock group were free from valve-related death (Fig 2). Statistical analysis showed no significant difference between the two groups. The linearized rates were.9% 2.3% per patient-year for the Carpentier-Edwards group and.9% f.4% per patient-year for the Hancock group (Table 4). The causes of valve-related death are listed in Table 5. ncluding sudden death in the causes of valve-related death, 83% & 4.8% of the patients in the Carpentier- Edwards group and 76% 2 8.2% of those in the Hancock group were free from valve-related death. Again, no significant difference was seen between the two groups. Throm boembolism On an actuarial basis, 95% & 2% of the patients in the Carpentier-Edwards group and 9% 2 3.8% of the patients in the Hancock group were free from thromboembolic complications at years (Fig 3). The linearized rates were.8% &.3% and.% 2.4% per patient-year, respectively (see Table 4). Differences between the two groups were not significant. Two fatal episodes of thrombotic valvular occlusion occurred in the Carpentier- Edwards group and one in the Hancock group. The other thromboembolic complications in both groups were transient and regressive. Carpentier-Edwards Hancock Complication (n = 47) (n = 6) Valve-related death Thromboembolism Structural valve deterioration Reoperation Valve failure.9 f.3.8 t t.5.9 t.4.? t ?.6 4.? f ~...f...i...p... k-a 94 7t 2 W! 9'38.. m Anticoagulant-related?.3.3 t.4 ' hemorrhage Valve-related mortality and 4.8 t f:. morbidity a Data are shown as percent per patient-year. Data are shown as the Fig 3. Actuarial curves of freedom frorn thromboe~bozisrn. C-E = Carpentier-Edwards; HCK = Hancock.) mean t the standard error of the mean C-E HCK
4 Ann Thorac Surg 989;48:54-9 PERER ET AL m 65t ? C-E *. Table 6. Causes of Reoperation Carpentier-Edwards Hancock Cause (n = 47) (n = 6) Structural Thrombosis valve deterioration Periprosthetic leak 3 4 Endocarditis HCK nadequate size.. ; i i i i j Total Fig 4. Actuarial representation of freedom from structural valve deterioration. (C-E = Carpentier-Edwards; HCK = Hancock.) Structural Valve Deterioration At years, 65% * 7.2% of the patients in the Carpentier- Edwards group and 66% * 7.2% of those in the Hancock group were free from structural valve deterioration (Fig 4). The difference was not significant. All of the patients with diagnosed structural valve deterioration were scheduled for an elective reoperation. Of the 24 patients with structural valve deterioration in the Carpentier-Edwards group and the 4 in the Hancock group who had reoperation, (4%) in the Carpentier-Edwards group died (postoperative heart failure) and 3 (2%) in the Hancock group died (2 of mediastinitis and of postoperative heart failure). Linearized rates are shown in Table 4. The prosthetic valves used at reoperation were as follows: 23 Starr-Edwards, porcine bioprostheses, and 5 St. Jude Medical. t is of note that in the Carpentier-Edwards group, four of the cases of structural valve deterioration occurred in the 8 patients younger than 35 years. n this same group, 6 cases occurred in the 76 patients younger than 55 years, and only eight cases were found in the 7 patients older than 55 years. The same situation prevailed in the Hancock group, with three cases of structural valve deterioration in the 7 patients younger than 35 years old. The 56 patients younger than 55 years experienced ten cases of structural valve deterioration, whereas the 5 patients older than 55 experienced four cases. Reoperation On an actuarial basis, at years, 64% & 6% in the Carpentier-Edwards group and 59% % in the Hancock group have undergone reoperation (Fig 5). The difference was not significant. The linearized rates of reoperation are shown in Table 4. The causes of reoperation are listed in Table 6. The mortality for reoperation was % in the Carpentier-Edwards group (3/29) and 7% in the Hancock group (4/23). Valve Failure At years, 6% * 6.5% of the patients in the Carpentier- Edwards group and 59% 5 7.3% of those in the Hancock group were free from valve failure (Fig 6). The difference was not significant. Causes of valve failure are listed in Table 7. t is noteworthy that in the Carpentier-Edwards group, 29 of the 34 patients with valve failure were able to have a reoperation and all the patients with valve failure in the Hancock group underwent reoperation. Seven patients in the Carpentier-Edwards group died as a result of valve failure (3, reoperation; 4, anticoagulant-related complication) and 4 in the Hancock group (4, reoperation). Anticoagulant-Related Hemorrhage At years, 92% 5 2.7% of the patients in the Carpentier- Edwards group and 85% * 5.5% of those in the Hancock : C-E HCK Fig 5. Actuarial curves of freedom from reoperation. (C-E = Carpentier-Edwards; HCK = Hancock.) k 59f73 47 ) S C-E 6 7 i HCK >.. Fig 6. Actuarial curves of freedom from valve failure. (C-E = Carpentier-Edwards; HCK = Hancock.)
5 58 PERER ET AL Ann Thorac Surg 989;48:54-9 Table 7. Causes of Valve Cause Carpentier-Edwards (n = 47) Hancock (n = 6) Structural valve 24 deterioration Thromboembolic 3 complications Periprosthetic leak 3 Endocarditis Anticoagulant-related 4 hemorrhage nadequate size Total ' C-E HCK Fig 8. Actuarial curves showing percentage of patients free from value-related mortality and morbidity. (C-E = Carpentier-Edwards; HCK = Hancock.) group were free from anticoagulant-related hemorrhage (Fig 7). The difference was not significant. Linearized rates are shown in Table 4. n the Carpentier-Edwards group, 4 patients died as a result of an anticoagulantrelated complication; none in the Hancock group died of this complication. Valve-Related Mortality and Morbidity Combining the incidence of thromboembolic and anticoagulation complications not resulting in reoperation or death with the incidence of valve failure yielded a composite function describing the incidence of valve-related mortality and morbidity. On an actuarial basis, 5% f 7.2% of the patients in the Carpentier-Edwards group and 49% * 7.5% of those in the Hancock group were free from valve-related complications at years. This difference was not significant (Fig 8). The linearized rates are shown in Table 4. Comment n spite of the extensive use since 974 of porcine bioprostheses, mainly the Carpentier-Edwards and the Hancock, few reports are available that compare the long-term results between these two valves [7-9. Using the methods described in a previous report from our institution [lo], this study seems appropriate because it compares two series of patients operated on in the same institution by the same team over a limited period of 5 years with a w."c'.l 5.., 92f C-E lo HCK La. follow-up of 7 to 2 years. The homogeneity of the two groups has been demonstrated only on the basis of clinical findings (age, preoperative functional class, preoperative cardiothoracic ratio, predominant functional lesion, etiology), as hernodynamic data were not available on all patients. One criticism that could be leveled is that the selection of the type of bioprosthesis placed was not randomized. Rather it was left to the discretion of each individual surgeon who habitually used the same prosthesis during the study period. The operative mortality was high. However, the operative risk has improved in the past years because of better myocardial protection. The current risk for isolated mitral valve replacement is 3%. Our -year survival of 55% and 5% for the Carpentier- Edwards and the Hancock groups, respectively, is similar to that in other reports on bioprostheses in the mitral position [ll, 2. However, the overall late survival, which is determined by patient-related factors and mostly by the condition of the heart at the time of operation, is not a sensitive indicator of the performance of a given prosthesis. The incidence of valve-related death may be a more accurate indicator of the risks associated with a given device. The actuarial rates of freedom from valve-related death (93% in the Carpentier-Edwards group and 85% in the Hancock group) revealed no significant difference. However, in a nonrandomized retrospective study, assessing the cause of death in a population who lived outside the hospital and who often died unobserved leads to a sustained possibility of error, as underlined by Hammond and colleagues [3]. As a result, we separated the patients who died suddenly. Most certainly, many of these patients died of an arrhythmia, but it is ikely that some patients died of a valve-related cause. The computation of valve-related mortality incorporating sudden death did not yield different results. One of the prime reasons for using porcine bioprosthetic valves is to decrease the incidence of thromboembolic complications compared with mechanical valves. As in other reports [4, 5, the rate of thromboembolic complications was low in the two groups (.8% 2.3% per patient-year in the Carpentier-Edwards group and
6 Ann Thorac Surg 989; PERER ET AL 59.% 5.4% per patient-year in the Hancock group). AS other studies [5, 6 have shown, most of the thromboembolic complications occurred within the first postoperative year. The incidence of anticoagulant-related hemorrhage, %?.3% per patient-year in the Carpentier-Edwards group and.3% 2.4% per patient-year in the Hancock group, was relatively high in this report, especially considering that 4 patients in the Carpentier-Edwards group died as a result of anticoagulation complications. Durability remains the major problem of tissue valves, and represents a serious concern for the patient and the surgeon. At the end of years, 35% of the patients in both groups have undergone reoperation for structural valve deterioration, an incidence frequently reported in the literature [ll, 7-9]. As in most other reports [7, 9, no difference was observed in the rate of structural valve deterioration between the Carpentier-Edwards prosthesis and the Hancock prosthesis. One exception was the study of Hartz and co-workers [2], which suggested that the deterioration rate of the Carpentier-Edwards bioprosthesis was less than that of the Hancock valve, but the follow-up was shorter. n both groups, the first cases of structural valve deterioration began occurring in the third postoperative year. One of the major issues with bioprostheses is the operative mortality associated with reoperation for structural valve deterioration. The operative mortality for valve re-replacement was 4% in the Carpentier-Edwards group and 2% in the Hancock group. n a larger series of 9 reoperations for structural valve deterioration of bioprostheses, we [2] found an operative mortality of 5.5%, a risk similar to that of primary operations. t is of note that in 25% of the reoperations for structural valve deterioration, a second kind of bioprosthesis was used (usually at the request of the patient) to avoid anticoagulation, provided failure did not occur within the first 8 years after implantation. This percentage is low compared with that of Magilligan and colleagues [7], who replaced 77% of degenerated valves in the mitral position with a different bioprosthesis. n summary, our study shows that the first-generation Carpentier-Edwards porcine bioprosthesis and the Hancock prosthesis produce comparable long-term results in the mitral position. The problem of structural valve failure in tissue valves may be eased in the recent products by the introduction of new methods of tissue preservation, lowpressure fixation, and improvements in calcium mitigation. References. Carpentier A, Lemaigre G, Ladislas R, et al. Biological factors affecting long term results of valvular heterografts. J Thorac Cardiovasc Surg 969;58: Miller DC, Oyer PE, Mitchel RS, et al. Performance characteristics of the Starr Edwards model 26 aortic valve pros- thesis beyond ten years. J Thorac Cardiovasc Surg 984; 88: Fabiani JN, Carpentier A. La mkthode actuarielle pour analyse statistique des rksultats cliniques et expknmentaux. Nouv Presse Med 977; Grunkemeier GL, Lambert LE, Bonchek L, Starr A. An improved statistical method for assessing the results of operation. Ann Thorac Surg 975;2: Grunkemeier GL, Thomas DR, Starr A. Statistical considerations in the analysis and reporting of time related events. Am J Cardiol 977;39: Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 977;35: Cobanoglu A, Jamieson WRE, Miller DC, et al. A triinstitutional comparison of tissue and mechanical valves using a patient-oriented definition of treatment failure. Ann Thorac Surg 987;43: Bolooki H, Kaiser GA, Mallon SM, Palatianos GM. Comparison of long-term results of Carpentier-Edwards and Hancock bioprosthetic valves. Ann Thorac Surg 986;42: Nistal F, Artiitano E, Gallo. Primary tissue valve degeneration in glutaraldehyde-preserved porcine bioprostheses: Hancock versus Carpentier-Edwards at 4- to 7-year followup. Ann Thorac Surg 986;42: Perier P, Bessou JP, Swanson JS, et al. Comparative evaluation of aortic valve replacement with Starr, Bjork and porcine valve prostheses. Circulation 985;72(Suppl 2):4-5.. Magilligan DJ, Lewis JW, Tilley 8, et al. The porcine bioprosthetic valve: twelve years later. J Thorac Cardiovasc Surg 985;89: Oyer PE, Stinson EB, Miller DC, et al. Clinical analysis of the Hancock porcine bioprosthesis. n: Cohn LH, Gallucci V, eds. Cardiac bioprostheses. New York: Yorke Medical Books, 982: Hammond GL, Geha AS, Hashim SW. Biological versus mechanical valves. J Thorac Cardiovasc Surg 987;93: Jamieson WRE, Pelletier CL, Janusz MT, et al. Five year evaluation of the Carpentier-Edwards porcine bioprosthesis. J Thorac Cardiovasc Surg 984;88: Oyer PE, Stinson EB, Griepp RB, et al. Long term evaluation of the porcine xenograft bioprosthesis. J Thorac Cardiovasc Surg 979;78: Perier P, Deloche A, Chauvaud S, et al. Comparative evaluation of mitral valve repair and replacement using Starr, Bjork and porcine valve prostheses. Circulation 984; 7O(Suppl ): Magilligan DJ, Lewis JW, Heinzerling RH, et al. Fate of a second porcine bioprosthetic valve. J Thorac Cardiovasc Surg 983;85: Schoen FJ, Collins JJ, Cohn LH. Long term failure rate and morphologic correlations in porcine bioprosthetic heart valves. Am J Cardiol 983;5: Gallo, Nistal F, Artiitano E. Six to ten year follow-up with patients with the Hancock cardiac bioprosthesis. J Thorac Cardiovasc Surg 986;92: Hartz RS, Fisher EB, Finkelmeier B, et al. An eight-year experience with porcine bioprosthetic cardiac valves. J Thorac Cardiovasc Surg 986;9: Perier P, Swanson J, Takriti A, et al. Decreasing operative risk in isolated valve re-replacement. n: Bodnar E, Yacoub M, eds. Biologic bioprosthetic valves. New York: Yorke Medical Books, 986:333-8.
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: Hancock I Vekus Carpentier-Edwards at 4- to 7-Years Follow-up
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: A Hancock I Vekus Edwards at 4- to 7-Years Follow-up Francisco Nistal, M.D., Edurne Artifiano, M.D., and Ignacio Gallo,
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationby Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D., L. H. Burr, M.D., R. T. Miyagishima, M.D.
Carpentier-Edwards Standard Porcine Bioprosthesis: Primary Tissue Failure (Structural Valve Deterioration) by Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D.,
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationAspirin or Coumadin as the Drug of Choice
Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis L. Nufiez, M.D., M. Gil Aguado, M.D., D. Celemin, M.D., A. Iglesias, M.D., and J. L. Larrea, M.D. ABSTRACT Eight
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationA prospective evaluation of the Bjbrk-Shiley, Hancock, and Carpentier-Edwards heart valve prostheses
THERAPY AND PREVENTION VALVE REPLACEMENT A prospective evaluation of the Bjbrk-Shiley, Hancock, and Carpentier-Edwards heart valve prostheses PETER BLOOMFIELD, M.R.C.P., ARTHUR H. KITCHIN, F.R.C.P.. DAVID
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationSurgery for Acquired Cardiovascular Disease
Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement W. R. E. Jamieson, MD, O. von Lipinski, MD, R. T.
More informationCARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP
CARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP M. R. Aupart, MD P. H. Neville, MD S. Hammami, MD A. L. Sirineili, MD Y. A. Meurisse, MD M. A. Marchand, MD Objective: The
More informationP substitutes since the introduction of the Ionescu-
Mitroflow Pericardial Valve: Long-Term Durability Daniel Y. Loisance, MD, Jean-Philippe Mazzucotelli, MD, Patrick C. Bertrand, MD, Philippe H. Deleuze, MD, and Jean-Paul Cachera, MD Department of Surgical
More informationIsolated Mitral Valve Replacement with the Hancock Bioprosthesis: A 13-Year Appraisal
Isolated Mitral Valve Replacement with the Hancock ioprosthesis: A 13-Year Appraisal Vincenzo Gallucci, M.D., berto ortolotti, M.D., Aldo Milano, M.D., Carlo Valfrk, M.D., Alessandro Mazzucco, M.D., and
More informationThe clinical experience reported in recent Western series has provided
Surgery for Acquired Cardiovascular Disease Yu et al Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease Hsi-Yu Yu, MD a Yi-Lwun Ho, MD b Shu-Hsun Chu, MD c Yih-Sharng
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationControversy exists regarding which valve type is best
Treatment of Endocarditis With Valve Replacement: The Question of Tissue Versus Mechanical Prosthesis Marc R. Moon, MD, D. Craig Miller, MD, Kathleen A. Moore, BS, Phillip E. Oyer, MD, PhD, R. Scott Mitchell,
More informationDurability of Pericardial Versus Porcine Aortic Valves
Journal of the American College of Cardiology Vol. 44, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.053
More informationP found suitable valve substitutes for clinical use.
Porcine Versus Pericardial Bioprostheses: A Comparison of Late Results in 1,593 Patients L. Conrad Pelletier, MD, Michel Carrier, MD, Yves Leclerc, MD, Gilles Lepage, MD, Pierre deguise, MD, and Ihor Dyrda,
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationThe use of mitral valve (MV) repair to correct mitral
Outcomes and Long-Term Survival for Patients Undergoing Repair Versus Effect of Age and Concomitant Coronary Artery Bypass Grafting Vinod H. Thourani, MD; William S. Weintraub, MD; Robert A. Guyton, MD;
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationCONTRIBUTION. Aortic valve replacement in young patients: long-term follow-up
CONTRIBUTION Aortic valve replacement in young patients: long-term follow-up DOUGLAS S. MOODIE, MD; USAMA HANHAN, MD; RICHARD STERBA, MD; DANIEL J. MURPHY, Jr, MD; ELIOT R. ROSENKRANZ, MD; ANDREA M. KOVACS,
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationVALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED?
VALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED? Eugene A. Grossi, MD Aubrey C. Galloway, MD Jeffrey S. Miller, MD Greg H. Ribakove, MD Alfred T. Culliford,
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationThe CarboMedics bileaflet prosthetic heart was introduced
The CarboMedics Valve: Experience With 1,049 Implants José M. Bernal, MD, José M. Rabasa, MD, Francisco Gutierrez-Garcia, MD, Carlos Morales, MD, J. Francisco Nistal, MD, and José M. Revuelta, MD Department
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationPorcine bioprosthesis use for surgical treatment of
Fifteen-Year Clinical Experience With the Biocor Porcine Bioprostheses in the Mitral Position Kaan Kırali, MD, Mustafa Güler, MD, Altuğ Tuncer, MD, Bahadır Dağlar, MD, Gökhan İpek, MD, Ömer Işık, MD, and
More informationHemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years
Hemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years Friedrich-Christian Riess, MD, Ralf Bader, MD, Eva Cramer, MD, Lorenz Hansen, MD, Bèr Kleijnen, MS, Gunther Wahl, MD,
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationPorcine Valve Durability in Children
Porcine Valve Durability in Children Jeffrey M. Dunn, M.D.* ABSTRACT Calcification of porcine heterograft valves may be greater in the pediatric than in the adult population. This multicenter study evaluates
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationRead at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.
STRUCTURAL VALVE DETERIORATION IN MITRAL REPLACEMENT SURGERY: COMPARISON OF CARPENTIER-EDWARDS SUPRA-ANNULAR PORCINE AND PERIMOUNT PERICARDIAL BIOPROSTHESES W. R. Eric Jamieson, MD a Michel A. Marchand,
More informationMitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients
Mitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients Kazutomo Minami, MD, Armin Zittermann, PhD, Sebastian Schulte-Eistrup, MD, Heinrich Koertke, MD, and Reiner
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More information164 Ann Thorac Surg 45: , Feb Copyright by The Society of Thoracic Surgeons
Heart Valve Replacement with the Bjork-Shiley Mbnostrut Valve: Early Results of a Multicenter Clinical Investigation Lars I. Thulin, M.D., William H. Bain, F.R.C.S., Hans H. Huysmans, M.D., Gerrit van
More informationBall Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation
Ball Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation Begonia Gometza, MD, and Carlos M. G. Duran, MD, PhD Department of Cardiovascular Diseases, King Faisal Specialist Hospital
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationThe risk-benefit ratio of mitral valve operation is
Degenerative Mitral Regurgitation: When Should We Operate? Malcolm J. R. Dalrymple-Hay, PhD, Mark Bryant, Richard A. Jones, MRCP, Stephen M. Langley, FRCS, Steven A. Livesey, FRCS, and James L. Monro,
More informationThe Starr-Edwards Valve
lacc Vol. 6, No.4 899 The Starr-Edwards Valve ALBERT STARR, MD, FACC Portland, Oregon This report reviews the results obtained with the current models of the Silastic ball valve, classifying the experience
More informationStandarized definition of bioprosthetic valve deterioration and failure
Translational aortic valve research. From biology to treatment Standarized definition of bioprosthetic valve deterioration and failure Anna Sonia Petronio, MD, FESC Head of Cardiac Catheterization Lab
More informationI will not discuss off label use or investigational use in my presentation.
I will not discuss off label use or investigational use in my presentation. Surgical valves Design and Durability Testing Potential Concerns Real Practice 1952-1962 1963-1966 1967-1969 1969-1977 1977-1984
More informationSmeloff-Cutter Prosthesis: 1- to 12-Year Follow-up David S. Starr, M.D., Gerald M. Lawrie, M.D., J. F. Howell, M.D., and George C. Morris, Jr., M.D.
Clinical Experience with the Smeloff-Cutter Prosthesis: 1- to 12-Year Follow-up David S. Starr, M.D., Gerald M. Lawrie, M.D., J. F. Howell, M.D., and George C. Morris, Jr., M.D. ABSTRACT To determine the
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationand Coronary Artery Surgery George M. Callard, M.D., John B. Flege, Jr., M.D., and Joseph C. Todd, M.D.
Combined Valvular and Coronary Artery Surgery George M. Callard, M.D., John B. Flege, Jr., M.D., and Joseph C. Todd, M.D. ABSTRACT Between July, 97, and March, 975,45 patients underwent combined valvular
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationLong-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
J Korean Med Sci 2007; 22: 1060-4 ISSN 1011-8934 DOI: 10.3346/jkms.2007.22.6.1060 Copyright The Korean Academy of Medical Sciences Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
More informationIndications and Late Results of Aortic Valve Repair
Indications and Late Results of Aortic Valve Repair Prof. Gebrine El Khoury Department of Cardiovascular and Thoracic Surgery Cliniques St. Luc Brussels, Belgium Aortic Valve Repair Question # 1 Can the
More informationA valve was initiated at the Medical University of
St. Jude Prosthesis for Aortic and Mitral Valve Replacement: A Ten-Year Experience John M. Kratz, MD, Fred A. Crawford, Jr, MD, Robert M. Sade, MD, Arthur J. Crumbley, MD, and Martha R. Stroud, MS Division
More informationBiological or mechanical valve prosthesis?
XXIX Giornate Cardiologiche Torinesi ADVANCES IN CARDIAC ARRHYTHMIAS AND GREAT INNOVATIONS IN CARDIOLOGY Turin, October 27-28, 2017 Centro Congressi Unione Industriale WHAT HAS CHANGED IN CARDIAC SURGERY?
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationMitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease
Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease Kenji Kuwaki, MD, PhD, Nobuyoshi Kawaharada, MD, PhD, Kiyofumi Morishita, MD, PhD, Tetsuya Koyanagi,
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationLong-Term Results With the Medtronic-Hall Valvular Prosthesis
Long-Term Results With the Medtronic-Hall Valvular Prosthesis Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Background. Although more than 170,000 Medtronic-
More informationAORTIC VALVE REPLACEMENT WITH FREEHAND AUTOLOGOUS PERICARDIUM
AORTIC VALVE REPLACEMENT WITH FREEHAND AUTOLOGOUS PERICARDIUM Fifty-one patients with a mean age of 31.2 years underwent aortic valve replacement with glutaraldehyde-treated autologous pericardium. Pure
More informationHeart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients
European Heart Journal (1990) 11, 583-591 Heart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients S. VOGT, A. HOFFMANN, J. ROTH, P. DUBACH,
More informationAortic Valve Replacement with Starr-Edwards Valves over 14 Years
Aortic Valve Replacement with Starr-Edwards Valves over 4 Years W. H. Wain, B.Sc., Ph.D., P. J. Drury, B.Sc., Ph.D., andd. N. Ross, F.R.C.S. ABSTRACT Three hundred thirteen patients underwent aortic valve
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationHigh Risk of Thromboemboli Early After Bioprosthetic Cardiac Valve Replacement
JACC Vol. 25, No. 5 1 111 April 1995:1111-9 SURGERY High Risk of Thromboemboli Early After Bioprosthetic Cardiac MAGDA HERAS, MD,*t JAMES H. CHESEBRO, MD, FACC,$ VALENTIN FUSTER, MD, PHD, FACC,~: WILLIAM
More informationLONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP
LONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP Bruno K. Podesser, MD a Gudrun Khuenl-Brady, MD a Ernst Eigenbauer,
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More informationMitral valve repair is the procedure of choice in SURGERY FOR ACQUIRED CARDIOVASCULAR DISEASE
SURGERY FOR ACQUIRED CARDIOVASCULAR DISEASE MITRAL VALVE REPAIR AND REPLACEMENT FOR RHEUMATIC DISEASE Terrence M. Yau, MD, MSc Yasser A. Farag El-Ghoneimi, MD Susan Armstrong, MSc Joan Ivanov, MSc Tirone
More informationAortic and Mitral Valve Incompetence: Long-Term Follow-Up (10 to 19 Years) of Patients Treated With the Starr-Edwards Prosthesis
93 lacc Vol. 3. No.4 April 19H4:93-8 Aortic and Mitral Valve Incompetence: Long-Term Follow-Up (1 to 19 ) of Patients Treated With the Starr-Edwards Prosthesis MICHAEL D. McGOON, MD, VALENTIN FUSTER, MD,
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationMitral valve replacement in patients under 65 years of age: mechanical or biological valves?
REVIEW C URRENT OPINION Mitral valve replacement in patients under 65 years of age: mechanical or biological valves? David C. Reineke, Paul Philipp Heinisch, Bernhard Winkler, Lars Englberger, and Thierry
More informationIschemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications
Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo
More informationLONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS
LONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS David S. Peterseim, MD Ye-Ying Cen, MA Srinivas Cheruvu, MHS Kevin Landolfo, MD Thomas M. Bashore, MD James E.
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationPATIENT BOOKLET MEDTRONIC SURGICAL VALVE REPLACEMENT. Tissue Valve for Aortic and Mitral Valve Replacement
PATIENT BOOKLET MEDTRONIC SURGICAL VALVE REPLACEMENT Tissue Valve for Aortic and Mitral Valve Replacement ARE MEDTRONIC SURGICAL TISSUE HEART VALVES RIGHT FOR YOU? Medtronic surgical heart valves are for
More informationExtension to medium and low risk patients? Friedrich Eckstein University Hospital Basel
TAVI CON Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel Extension to medium and low risk patients? In octogenerians already reality in most of the swiss clinics!?
More informationClinical validation of a new drug seeking Food and
THE STATISTICIAN S PAGE Prosthetic Heart Valves: Objective Performance Criteria Versus Randomized Clinical Trial Gary L. Grunkemeier, PhD, Ruyun Jin, MD, and Albert Starr, MD Providence Health System,
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More informationSurgery for mitral regurgitation Repair versus valve replacement*
European Heart Journal (1986) 7, 638-643 Surgery for mitral regurgitation versus valve replacement* H. P. KRAYENBUEHL Medical Policlinic, Cardiology, University Hospital, CH-8091, Zurich, Switzerland KEY
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationThe Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients
The Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients Michel R. Aupart, MD, Agnes L. Sirinelli, MD, Frank F. Diemont, MD, Yvon A. Meurisse, MD, Xavier B.
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationKinsing Ko, Thom de Kroon, Najim Kaoui, Bart van Putte, Nabil Saouti. St. Antonius Hospital, Nieuwegein, The Netherlands
Minimal Invasive Mitral Valve Surgery After Previous Sternotomy Without Aortic Clamping: Short- and Long Term Results of a Single Surgeon Single Institution Kinsing Ko, Thom de Kroon, Najim Kaoui, Bart
More informationW. Schlick, M.D., J. Mlczoch, M.D., G. Kronik, M.D., and E. Wolner, M.D.
Implantation of the Durornedics Bileaflet Cardiac Valve Prosthesis in 400 Patients W. Klepetko, M.D., A. Moritz, M.D., G. KhunlBrady, M.D., W. Schreiner, Ph.D., W. Schlick, M.D., J. Mlczoch, M.D., G. Kronik,
More informationPrognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards
European Heart Journal Supplements (1) 3 (Supplement Q), Q27 Q32 Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding
More informationOn October 3, 1977, the first St. Jude Medical (SJM)
The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Robert W. Emery, MD, Christopher C. Krogh, Kit V. Arom, MD, PhD, Ann M. Emery, RN, Kathy Benyo-Albrecht,
More informationThe Medtronic-Hall Cardiac Valve:
The Medtronic-Hall Cardiac Valve: 7?h Years' Clinical Experience Regent L. Beaudet, M.D., Normand L. Poirier, M.D., Daniel Doyle, M.D., Gisde Nakhlb, M.Sc., and Christiane Gauvin, M.T. ABSTRACT Clinical
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationAortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients
Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients Augusto D Onofrio, MD, Stefano Auriemma, MD, Paolo Magagna, MD, Alessandro Favaro, MD,
More informationIn patients with prosthetic heart
CLINICIAN UPDATE Prosthetic Heart Valves and Pregnancy Lynne Hung, MD; Shahbudin H. Rahimtoola, MB, FRCP, MACP, MACC, DSc (Hon) In patients with prosthetic heart valves (PHV), pregnancy is associated with
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More informationSurgery for Valvular Heart Disease. Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse
Surgery for Valvular Heart Disease Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse Dania Mohty, MD; Thomas A. Orszulak, MD; Hartzell V. Schaff, MD; Jean-Francois
More information